Fig. 2: Clinical outcomes with CAPOX, trastuzumab and bevacizumab in patients with previously untreated advanced HER2 + GEA. | Nature Communications

Fig. 2: Clinical outcomes with CAPOX, trastuzumab and bevacizumab in patients with previously untreated advanced HER2 + GEA.

From: Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

Fig. 2

A Waterfall Plot showing Best Response per RECIST 1.1. B Spider plot demonstrates evolution of radiographic response over time as measured by the change in sum of target lesions measured by RECIST 1.1 (N = 36). Progression free survival (PFS, C) and Overall survival (OS, D), respectively, for the entire cohort. Progression free survival E and Overall survival F, respectively, stratified by subjects with tumors that were IHC HER2 3+ vs. IHC HER2 2+ (N = 33). P-value was calculated using two-tailed log rank test E, F.

Back to article page